In vitro structure–activity relationships and forensic case series of emerging 2-benzylbenzimidazole ‘nitazene’ opioids
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
2-Benzylbenzimidazole ‘nitazene’ opioids are presenting a growing threat to public health. Although various nitazenes were previously studied, systematic comparisons of the effects of different structural modifications to the 2-benzylbenzimidazole core structure on μ-opioid receptor (MOR) activity are limited. Here, we assessed in vitro structure–activity relationships of 9 previously uncharacterized nitazenes alongside known structural analogues. Specifically, we focused on MOR activation by ‘ring’ substituted analogues (i.e., N -pyrrolidino and N -piperidinyl modifications), ‘desnitazene’ analogues (lacking the 5-nitro group), and N -desethyl analogues. The results from two in vitro MOR activation assays (β-arrestin 2 recruitment and inhibition of cAMP accumulation) showed that ‘ring’ modifications overall yield highly active drugs. With the exception of 4′-OH analogues (which are metabolites), N -pyrrolidino substitutions were generally more favorable for MOR activation than N -piperidine substitutions. Furthermore, removal of the 5-nitro group on the benzimidazole ring consistently caused a pronounced decrease in potency. The N -desethyl modifications showed important MOR activity, and generally resulted in a slightly lowered potency than comparator nitazenes. Intriguingly, N -desethyl isotonitazene was the exception and was consistently more potent than isotonitazene. Complementing the in vitro findings and demonstrating the high harm potential associated with many of these compounds, we describe 85 forensic cases from North America and the United Kingdom involving etodesnitazene, N -desethyl etonitazene, N -desethyl isotonitazene, N -pyrrolidino metonitazene, and N -pyrrolidino protonitazene. The low-to-sub ng/mL blood concentrations observed in most cases underscore the drugs’ high potencies. Taken together, by bridging pharmacology and case data, this study may aid to increase awareness and guide legislative and public health efforts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the presence of a nitazene analogue even at trace amounts, which could be below the cut-off for detection with NTS, may readily give rise to dangerous opioid effects in (unknowing) users.”
From Nitazene test strips: a laboratory evaluation (2024) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“we found e.g. etodesnitazene to have a similar in vitro potency and efficacy as fentanyl [7, 13]”
From Nitazene test strips: a laboratory evaluation (2024) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The recent emergence of ultrapotent nitazenes, the N‐pyrrolidino analogues, has amplified public health concern because their potency have been reported to be up to 45 times that of fentanyl [7].”
From Early identification of the use of potent benzylbenzimidazoles (nitazenes) through wastewater analysis: Two years of data from 22 countries (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“They are μ opioid receptor agonists with potency that ranges from that comparable to fentanyl (e.g. metonitazene), to 45‐fold greater (N‐desethyl isotonitazene), based on in vitro μ‐opioid receptor activity assays [7].”
From Early identification of the use of potent benzylbenzimidazoles (nitazenes) through wastewater analysis: Two years of data from 22 countries (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“N‐Pyrrolidino etonitazene (etonitazepyne) differs structurally from other nitazenes [28] in a way that makes etonitazepyne approximately 40 times more potent than fentanyl [7], with greater activation of the β‐arrestin2 pathway (EC50 = 0.548 nM).”
From Early identification of the use of potent benzylbenzimidazoles (nitazenes) through wastewater analysis: Two years of data from 22 countries (2025) · cites this paper as [7]
Experimental — accuracy not yet measured
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gillis, A., Gondin, A. B., Kliewer, A., Sanchez, J., Lim, H. D., Alamein, C., Manandhar, P., Santiago, M., Fritzwanker, S., Schmiedel, F., et al. (2020) · Science Signaling · doi:10.1126/scisignal.aaz3140 · Cited by 336 · cited 1×
“Therefore, the proposed in vitro SAR trends, indicating a (very) high MOR activating potential of many of the investigated compounds, may be cautiously extrapolated to the in vivo setting (Gillis et al. 2020; Tsai et al. 2024).”
BackgroundFriedman, J., & Shover, C. L. (2023) · Addiction · doi:10.1111/add.16318 · Cited by 322
Zhang, R., & Xie, X. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.173 · Cited by 317 · cited 1×
“…levels (upstream and further downstream) in a common cellular background (HEK 293T cells) can be considered a strength of this study, it is important to consider some inherent differences in the characteristics of the assays that were deployed (Zhang and Xie 2012; Vandeputte et al. 2022d).”
BackgroundVandeputte, M. M., Van Uytfanghe, K., Layle, N. K., St. Germaine, D. M., Iula, D. M., & Stove, C. P. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00064 · Cited by 161
Self-citationThe atypical chemokine receptor ACKR3/CXCR7 is a broad-spectrum scavenger for opioid peptides
Meyrath, M., Szpakowska, M., Zeiner, J., Massotte, L., Merz, M. P., Benkel, T., Simon, K., Ohnmacht, J., Turner, J. D., Krüger, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16664-0 · Cited by 152 · cited 1×
“The pNBe2 expression vector encoding the human MOR, C-ter-minally tagged with SmBiT (part of the NanoBiT ® system), was kindly provided by Dr. Andy Chevigné and was previously reported by Meyrath et al. (2020).”
MethodCharbogne, P., Kieffer, B. L., & Befort, K. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.028 · Cited by 147 · cited 1×
“MOR is the main molecular target for most therapeutic and abused opioids (Charbogne et al. 2014).”
BackgroundIsotonitazene Quantitation and Metabolite Discovery in Authentic Forensic Casework
Krotulski, A. J., Papsun, D. M., Kacinko, S. L., & Logan, B. K. (2020) · Journal of Analytical Toxicology · doi:10.1093/jat/bkaa016 · Cited by 146 · cited 7×
“N -Desethyl etonitazene and N -desethyl isotonitazene are metabolites of etonitazene and isotonitazene, respectively (Taoussi et al. 2024; Kanamori et al. 2024; Krotulski et al. 2020).”
BackgroundMethodInfluentialSelf-citationDARK Classics in Chemical Neuroscience: Etonitazene and Related Benzimidazoles
Ujváry, I., Christie, R., Evans-Brown, M., Gallegos, A., Jorge, R., de Morais, J., & Sedefov, R. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00037 · Cited by 141 · cited 14×
“This allowed us to further build on known SAR trends within the nitazene class, focusing on the structural modifications observed in nitazenes that have recently emerged on the NPS markets in the U.S. and around the world.”
BackgroundInfluentialLaing, M. K., Ti, L., Marmel, A., Tobias, S., Shapiro, A. M., Laing, R., Lysyshyn, M., & Socías, M. E. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103169 · Cited by 124 · cited 11×
“This allowed us to further build on known SAR trends within the nitazene class, focusing on the structural modifications observed in nitazenes that have recently emerged on the NPS markets in the U.S. and around the world.”
BackgroundInfluentialBlanckaert, P., Cannaert, A., Van Uytfanghe, K., Hulpia, F., Deconinck, E., Van Calenbergh, S., & Stove, C. (2020) · Drug Testing and Analysis · doi:10.1002/dta.2738 · Cited by 116 · cited 1×
“Apart from occasional identifications of etonitazene between 1966 and 2003 (Brandenberger 1974; Sorokin 1999; Sorokin et al. 1999; Reavy 2003; Morris 2009), it was not until 2019 that the first nitazene was identified on the recreational drug market (Blanckaert et al. 2020; Vandeputte et al. 2021).”
BackgroundSelf-citationSynthese basisch substituierter, analgetisch wirksamer Benzimidazol-Derivate
Hunger, A., Kebrle, J., Rossi, A., & Hoffmann, K. J. (1957) · Cellular and Molecular Life Sciences · doi:10.1007/bf02161116 · Cited by 103 · cited 1×
“A mouse tail-flick assay revealed that the antinociceptive potency of etonita-zene, the prototypical drug in the series and the previously described most potent analogue, was 1000-fold higher than that of morphine (Gross and Turrian 1957; Hunger et al. 1957, 1960a, b).”
BackgroundWalton, S. E., Krotulski, A. J., & Logan, B. K. (2022) · Journal of Analytical Toxicology · doi:10.1093/jat/bkab117 · Cited by 92 · cited 1×
“OH nitazene is a universal metabolite of all nitazenes with alkoxy chain modifications only (Taoussi et al. 2024; Kanamori et al. 2024; Walton et al. 2021).”
BackgroundSelf-citationKrotulski, A. J., Papsun, D. M., Walton, S. E., & Logan, B. K. (2021) · Drug Testing and Analysis · doi:10.1002/dta.3115 · Cited by 91 · cited 4×
“…isotonitazene with that of other recent NSOs such as isotonitazene (Krotulski et al. 2020), brorphine (Kro-tulski et al. 2021a), metonitazene (Krotulski et al. 2021b), and (to a lesser extent) N -pyrrolidino etonitazene (Vandep-utte et al. 2022b), it appears that their distribution across…”
BackgroundMethodInfluentialSelf-citationMontanari, E., Madeo, G., Pichini, S., Busardò, F. P., & Carlier, J. (2022) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000970 · Cited by 89
Nitazenes—Heralding a Second Wave for the UK Drug-Related Death Crisis?
Holland, A., Copeland, C. S., Shorter, G. W., Connolly, D. J., Wiseman, A., Mooney, J., Fenton, K., & Harris, M. (2024) · The Lancet Public Health · doi:10.1016/s2468-2667(24)00001-x · Cited by 86 · cited 1×
“This is necessary, as nitazenes are presenting a growing threat to public health in Europe and elsewhere (Holland et al. 2024; Giraudon et al. 2024).”
BackgroundMueller, F., Bogdal, C., Pfeiffer, B., Andrello, L., Ceschi, A., Thomas, A., & Grata, E. (2021) · Forensic Science International · doi:10.1016/j.forsciint.2021.110686 · Cited by 82
Vandeputte, M. M., Krotulski, A. J., Walther, D., Glatfelter, G. C., Papsun, D., Walton, S. E., Logan, B. K., Baumann, M. H., & Stove, C. P. (2022) · Archives of Toxicology · doi:10.1007/s00204-022-03276-4 · Cited by 80 · cited 6×
“Previous in vitro studies (Vandeputte et al. 2022b, e; Tsai et al. 2024) showed that both N -pyrrolidino and N -piperidinyl substitutions of the amine side chain are well-tolerated in terms of MOR activation, with N -pyrro- lidino etonitazene being equally potent and N -piperidinyl etonitazene…”
BackgroundMethodResultInfluentialSelf-citationThe Rise and Fall of Isotonitazene and Brorphine: Two Recent Stars in the Synthetic Opioid Firmament
Vandeputte, M. M., Krotulski, A. J., Papsun, D. M., Logan, B. K., & Stove, C. P. (2022) · Journal of Analytical Toxicology · doi:10.1093/jat/bkab082 · Cited by 71 · cited 1×
“1, 2), which quickly populated the NSO market and has since been implicated in hundreds of deaths worldwide, stressing the dangerous nature of this family of opioids (EMCDDA 2020; Krotulski et al. 2020; Muel-ler et al. 2021; Vandeputte et al. 2022a; Montanari et al. 2022).”
BackgroundSelf-citationHunger, A., Kebrle, J., Rossi, A., & Hoffmann, K. (1960) · Helvetica Chimica Acta · doi:10.1002/hlca.19600430412 · Cited by 70 · cited 4×
“A mouse tail-flick assay revealed that the antinociceptive potency of etonita-zene, the prototypical drug in the series and the previously described most potent analogue, was 1000-fold higher than that of morphine (Gross and Turrian 1957; Hunger et al. 1957, 1960a, b).”
BackgroundInfluentialTo Measure or Not to Measure? That is the NPS Question
Gerostamoulos, D., Elliott, S., Walls, H. C., Peters, F. T., Lynch, M., & Drummer, O. H. (2016) · Journal of Analytical Toxicology · doi:10.1093/jat/bkw013 · Cited by 65 · cited 1×
“In addition, the interpretation of in vivo concentrations is complicated by various factors, including interindividual differences in opioid tolerance (Gerostamoulos et al. 2016; Vandeputte et al. 2022e) and whether the users were knowingly using nitazenes or not.”
BackgroundThe Opioid Epidemic: Moving Toward an Integrated, Holistic Analytical Response
Morrow, J. B., Ropero-Miller, J. D., Catlin, M. L., Winokur, A. D., Cadwallader, A. B., Staymates, J. L., Williams, S. R., McGrath, J. G., Logan, B. K., McCormick, M. M., et al. (2019) · Journal of Analytical Toxicology · doi:10.1093/jat/bky049 · Cited by 65 · cited 1×
“Hence, in line with earlier recommendations that the opioid crisis should be dealt with in a multidisciplinary manner (Baumann et al. 2018; Morrow et al. 2019), and not solely by, e.g., isolated case reports or pharmacology-only studies, this study aimed at bridging these two areas.”
BackgroundSelf-citationIn vitro functional characterization of a panel of non-fentanyl opioid new psychoactive substances
Vandeputte, M. M., Cannaert, A., & Stove, C. P. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02855-7 · Cited by 65 · cited 1×
“In line with previous studies from our group (Vandeputte et al. 2020, 2021; Pottie et al. 2020a), the normalized AUC values from the highest concentration(s) of each compound were excluded in case of a reduction of 20% or more compared to the AUC of the subsequent dilution, to avoid inadvert-ent…”
ResultSelf-citationÜber Benzimidazolderivate mit starker analgetischer Wirkung
Gross, F., & Turrian, H. (1957) · Cellular and Molecular Life Sciences · doi:10.1007/bf02161117 · Cited by 62 · cited 1×
“A mouse tail-flick assay revealed that the antinociceptive potency of etonita-zene, the prototypical drug in the series and the previously described most potent analogue, was 1000-fold higher than that of morphine (Gross and Turrian 1957; Hunger et al. 1957, 1960a, b).”
BackgroundPost Mortem Redistribution of Drugs: Current State of Knowledge
Sastre, C., Bartoli, C., Baillif-Couniou, V., Leonetti, G., & Pelissier-Alicot, A.-L. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612823666170622111739 · Cited by 58 · cited 1×
“However, conclusions should be drawn with caution due to variations in sample size and blood sampling site (Sastre et al. 2017).”
BackgroundPharmacological Research as a Key Component in Mitigating the Opioid Overdose Crisis
Baumann, M. H., Kopajtic, T. A., & Madras, B. K. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.09.006 · Cited by 57 · cited 1×
“Hence, in line with earlier recommendations that the opioid crisis should be dealt with in a multidisciplinary manner (Baumann et al. 2018; Morrow et al. 2019), and not solely by, e.g., isolated case reports or pharmacology-only studies, this study aimed at bridging these two areas.”
BackgroundVasudevan, L., Vandeputte, M., Deventer, M., Wouters, E., Cannaert, A., & Stove, C. P. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113910 · Cited by 55 · cited 3×
“A previously reported, stable cell-based assay (Cannaert et al. 2018; Vasudevan et al. 2020) was used to monitor MOR-mediated G protein-independent pathway activation.”
MethodSelf-citationPottie, E., Dedecker, P., & Stove, C. P. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114251 · Cited by 55 · cited 5×
“In line with previous studies from our group (Vandeputte et al. 2020, 2021; Pottie et al. 2020a), the normalized AUC values from the highest concentration(s) of each compound were excluded in case of a reduction of 20% or more compared to the AUC of the subsequent dilution, to avoid inadvert-ent skewing of the concent…”
MethodResultInfluentialSelf-citationActivity-Based Concept to Screen Biological Matrices for Opiates and (Synthetic) Opioids
Cannaert, A., Vasudevan, L., Friscia, M., Mohr, A. L. A., Wille, S. M. R., & Stove, C. P. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2018.289496 · Cited by 54 · cited 1×
“A previously reported, stable cell-based assay (Cannaert et al. 2018; Vasudevan et al. 2020) was used to monitor MOR-mediated G protein-independent pathway activation.”
MethodSelf-citationMu-Opioid Receptor Selective Superagonists Produce Prolonged Respiratory Depression
Malcolm, N. J., Palkovic, B., Sprague, D. J., Calkins, M. M., Lanham, J. K., Halberstadt, A. L., Stucke, A. G., & McCorvy, J. D. (2023) · iScience · doi:10.1016/j.isci.2023.107121 · Cited by 53 · cited 7×
“While this is in line with previous in vitro (Vandeputte et al. 2021, 2023; Kozell et al. 2024; Tsai et al. 2024) and in vivo (rat) findings (Walton et al. 2023; Vandeputte et al. 2023), Malcolm et al. (2023) did not observe this trend in in vitro and in vivo assays.”
BackgroundResultInfluentialGlatfelter, G. C., Vandeputte, M. M., Chen, L., Walther, D., Tsai, M.-H. M., Shi, L., Stove, C. P., & Baumann, M. H. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06451-2 · Cited by 52 · cited 7×
“Shorter (i.e., methyl) or longer (i.e., propyl and butyl) tails lead to less potent analogues (Vandeputte et al. 2021; Kanamori et al. 2023; Glatfelter et al. 2023; Kozell et al. 2024).”
BackgroundMethodResultInfluentialSelf-citationHunger, A., Kebrle, J., Rossi, A., & Hoffmann, K. (1960) · Helvetica Chimica Acta · doi:10.1002/hlca.19600430323 · Cited by 49
De Luca, M. A., Tocco, G., Mostallino, R., Laus, A., Caria, F., Musa, A., Pintori, N., Ucha, M., Poza, C., Ambrosio, E., et al. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109263 · Cited by 48 · cited 3×
“…nitazenes have been characterized both in vitro and in vivo for their opioid activity (Ujváry et al. 2021; Vandeputte et al. 2021, 2022b, e, 2023; De Luca et al. 2022; Kanamori et al. 2023; Walton et al. 2023; Malcolm et al. 2023; Glatfelter et al. 2023; Kozell et al. 2024; Tsai et al. 2024),…”
BackgroundPottie, E., Tosh, D. K., Gao, Z.-G., Jacobson, K. A., & Stove, C. P. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113934 · Cited by 47 · cited 5×
“In line with previous studies from our group (Vandeputte et al. 2020, 2021; Pottie et al. 2020a), the normalized AUC values from the highest concentration(s) of each compound were excluded in case of a reduction of 20% or more compared to the AUC of the subsequent dilution, to avoid inadvert-ent skewing of the concent…”
MethodResultInfluentialSelf-citationKrotulski, A. J., Papsun, D. M., Noble, C., Kacinko, S. L., & Logan, B. K. (2021) · Journal of Forensic Sciences · doi:10.1111/1556-4029.14623 · Cited by 47 · cited 7×
“N -Desethyl etonitazene and N -desethyl isotonitazene are metabolites of etonitazene and isotonitazene, respectively (Taoussi et al. 2024; Kanamori et al. 2024; Krotulski et al. 2020).”
BackgroundMethodInfluentialSelf-citationVandeputte, M. M., Verougstraete, N., Walther, D., Glatfelter, G. C., Malfliet, J., Baumann, M. H., Verstraete, A. G., & Stove, C. P. (2022) · Archives of Toxicology · doi:10.1007/s00204-022-03294-2 · Cited by 44 · cited 2×
“In addition, the interpretation of in vivo concentrations is complicated by various factors, including interindividual differences in opioid tolerance (Gerostamoulos et al. 2016; Vandeputte et al. 2022e) and whether the users were knowingly using nitazenes or not.”
BackgroundSelf-citationControl of fentanyl-related substances in China
Bao, Y., Meng, S., Shi, J., & Lü, L. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30218-4 · Cited by 42 · cited 2×
“Opioids with diverse chemical structures have emerged in response to class-wide bans on fentanyl Liam M. De Vrieze and Sara E. Walton have contributed equally to this work. analogues in the U.S. and China (Bao et al. 2019; UNODC 2020; 117th Congress 2021), and NSOs with a 2-benzylb-enzimidazole core (Fig.”
BackgroundKozell, L. B., Eshleman, A. J., Wolfrum, K. M., Swanson, T. L., Bloom, S. H., Benware, S., Schmachtenberg, J. L., Schutzer, K. A., Schutzer, W. E., Janowsky, A., et al. (2024) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.123.002052 · Cited by 42 · cited 11×
“Previous in vitro and in vivo data showed that removal of the 5-nitro group leads to a significant reduction in potency (Hunger et al. 1960a; Van-deputte et al. 2021; Kozell et al. 2024).”
BackgroundResultInfluentialNitazenes represent a growing threat to public health in Europe
Giraudon, I., Abel-Ollo, K., Vanaga-Arāja, D., Heudtlass, P., & Griffiths, P. (2024) · The Lancet Public Health · doi:10.1016/s2468-2667(24)00024-0 · Cited by 40 · cited 1×
“This is necessary, as nitazenes are presenting a growing threat to public health in Europe and elsewhere (Holland et al. 2024; Giraudon et al. 2024).”
BackgroundTaoussi, O., Berardinelli, D., Zaami, S., Tavoletta, F., Basile, G., Kronstrand, R., Auwärter, V., Busardò, F. P., & Carlier, J. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03735-0 · Cited by 40
Analysis of highly potent synthetic opioid nitazene analogs and their positional isomers
Kanamori, T., Okada, Y., Segawa, H., Yamamuro, T., Kuwayama, K., Tsujikawa, K., & Iwata, Y. T. (2023) · Drug Testing and Analysis · doi:10.1002/dta.3415 · Cited by 39 · cited 3×
“…characterized both in vitro and in vivo for their opioid activity (Ujváry et al. 2021; Vandeputte et al. 2021, 2022b, e, 2023; De Luca et al. 2022; Kanamori et al. 2023; Walton et al. 2023; Malcolm et al. 2023; Glatfelter et al. 2023; Kozell et al. 2024; Tsai et al. 2024), the continuing…”
BackgroundVandeputte, M. M., Tsai, M.-H. M., Chen, L., Glatfelter, G. C., Walther, D., Stove, C. P., Shi, L., & Baumann, M. H. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.109939 · Cited by 39
Self-citationPucci, M., Singh Jutley, G., Looms, J., & Ford, L. (2024) · Clinical Toxicology · doi:10.1080/15563650.2024.2309321 · Cited by 37 · cited 1×
“In those cases, the patients were each unaware that they had taken a nitazene (Pucci et al. 2024).”
BackgroundKilloran, S., McNamara, S., Kavanagh, P., O'Brien, J., & Lakes, R. (2025) · Drug Testing and Analysis · doi:10.1002/dta.3707 · Cited by 34 · cited 1×
“Furthermore, the detection of N -pyrrolidino protonitazene in 6 cases that originated from the U.K. aligns with the recent reports of its involvement in various postmortem and overdose cases in Ireland (Killeen et al. 2024; Killoran et al. 2024; HSE 2024; Burnhill 2024).”
MethodWalton, S. E., Krotulski, A. J., Glatfelter, G. C., Walther, D., Logan, B. K., & Baumann, M. H. (2023) · Psychopharmacology · doi:10.1007/s00213-022-06292-5 · Cited by 33
Self-citation�ber neue starkwirkende Analgetika und ihre klinische Erprobung
Bromig, G. (1958) · Klinische Wochenschrift · doi:10.1007/bf01486702 · Cited by 29 · cited 1×
“Despite their promising antinociceptive properties, nitazenes were never marketed, possibly due to a high risk of adverse effects (Bromig 1958; Ujváry et al. 2021).”
BackgroundTsai, M.-H. M., Chen, L., Baumann, M. H., Canals, M., Javitch, J. A., Lane, J. R., & Shi, L. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00750 · Cited by 27 · cited 8×
“Previous in vitro studies (Vandeputte et al. 2022b, e; Tsai et al. 2024) showed that both N -pyrrolidino and N -piperidinyl substitutions of the amine side chain are well-tolerated in terms of MOR activation, with N -pyrro- lidino etonitazene being equally potent and N -piperidinyl etonitazene…”
BackgroundResultInfluentialBerardinelli, D., Taoussi, O., Carlier, J., Tini, A., Zaami, S., Sundermann, T., Busardò, F. P., & Auwärter, V. (2024) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-1360 · Cited by 26 · cited 4×
“However, dedicated studies on the in vivo human metabolism of ‘ring’ nitazenes are warranted (Berardinelli et al. 2024).”
BackgroundInfluentialVandeputte, M. M., Persson, M., Walther, D., Vikingsson, S., Kronstrand, R., Baumann, M. H., Gréen, H., & Stove, C. P. (2022) · Archives of Toxicology · doi:10.1007/s00204-021-03207-9 · Cited by 24 · cited 1×
“C ) allowed a comparative assessment of potencies (Vandeputte et al. 2022c) that was highly similar between both assays.”
ResultSelf-citationVandeputte, M. M., Vasudevan, L., & Stove, C. P. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108161 · Cited by 23 · cited 4×
“…levels (upstream and further downstream) in a common cellular background (HEK 293T cells) can be considered a strength of this study, it is important to consider some inherent differences in the characteristics of the assays that were deployed (Zhang and Xie 2012; Vandeputte et al. 2022d).”
BackgroundMethodInfluentialSelf-citationKilleen, N., Lakes, R., Webster, M., Killoran, S., McNamara, S., Kavanagh, P., Eagleton, M., McCormack, S., Micheau, E., Moughty, A., et al. (2024) · Addiction · doi:10.1111/add.16525 · Cited by 22 · cited 1×
“Furthermore, the detection of N -pyrrolidino protonitazene in 6 cases that originated from the U.K. aligns with the recent reports of its involvement in various postmortem and overdose cases in Ireland (Killeen et al. 2024; Killoran et al. 2024; HSE 2024; Burnhill 2024).”
MethodKanamori, T., Okada, Y., Segawa, H., Yamamuro, T., Kuwayama, K., Tsujikawa, K., & Iwata, Y. T. (2025) · Drug Testing and Analysis · doi:10.1002/dta.3705 · Cited by 16 · cited 2×
“OH nitazene is a universal metabolite of all nitazenes with alkoxy chain modifications only (Taoussi et al. 2024; Kanamori et al. 2024; Walton et al. 2021).”
BackgroundChaturvedi, K., Hewamanna, I., Pandey, P., Khan, W., Wang, Y., Chittiboyina, A. G., Doerksen, R. J., & Godfrey, M. (2023) · Molecules · doi:10.3390/molecules28041601 · Cited by 8
Fogarty, M., Walton, S., Papsun, D. M., Logan, B. K., & Krotulski, A. J. (2022) · Annales de Toxicologie Analytique · doi:10.1016/j.toxac.2022.06.178 · Cited by 2 · cited 1×
“Quantitative determination of etodesnitazene, N -desethyl iso-tonitazene, N -pyrrolidino metonitazene, and N -pyrrolidino protonitazene in biological specimens was performed using LC-QQQ-MS employing a standard addition approach (Kro-tulski et al. 2020, 2021a; Fogarty et al. 2022).”
MethodSelf-citation
Research works printed but not linked: 7
- Brandenberger H (1974) Rolle des massenspektrometers im toxikologisch-chemischen laboratorium. Dtsch Lebensm-Rundsch 70:31–39
- EMCDDA (2020) Report on the risk assessment of N,N-diethyl-2-[[4-(1-methylethoxy) phenyl] methyl]-5-nitro-1H-benzimidazole-1-ethanamine (isotonitazene) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended). Publications Office, Luxembourg
- EMCDDA (2023) European drug report 2023: trends and developments. Publications Office of the European Union, Luxembourg
- Krotulski A, Papsun D, Walton SE, Logan BK (2022) Benzo-dope: an increasingly prevalent drug combination of significant toxicological relevance. Society of forensic toxicologist (SOFT)- 2022 conference meeting
- Sorokin VI (1999) Illegal synthesis of etonitazene. J Clan Lab Invest Chem Assoc 9:20
- Sorokin VI, Ponkratov KV, Drozdov MA (1999) Etonitazene encountered in Moscow. Microgram 32:239
- UNODC (2020) The growing complexity of the opioid crisis. Global SMART update (2020) vol 24. Austria, Vienna
Cited by
Vandeputte, M. M., & Stove, C. P. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110470 · Cited by 36
Self-citationVandeputte, M. M., Glatfelter, G. C., Walther, D., Layle, N. K., St. Germaine, D. M., Ujváry, I., Iula, D. M., Baumann, M. H., & Stove, C. P. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107503 · Cited by 35
Self-citationNitazene test strips: a laboratory evaluation
De Vrieze, L. M., Stove, C. P., & Vandeputte, M. M. (2024) · Harm Reduction Journal · doi:10.1186/s12954-024-01078-8 · Cited by 34
“Nitazene opioids generally display high levels of opioid activity, with potencies and efficacies often exceeding that of fentanyl [7, 12, 13].”
BackgroundInfluentialSelf-citationNitazenes: review of comparative pharmacology and antagonist action
Stangeland, M., Dale, O., & Skulberg, A. K. (2025) · Clinical Toxicology · doi:10.1080/15563650.2025.2504133 · Cited by 34
Bade, R., Nadarajan, D., Hall, W., Brown, J. A., NPS Wastewater Consortium, & Schumann, J. (2025) · Addiction · doi:10.1111/add.70027 · Cited by 28
Metadata
- Authors
- De Vrieze, L. M., Walton, S. E., Pottie, E., Papsun, D., Logan, B. K., Krotulski, A. J., Stove, C. P., & Vandeputte, M. M.
- Affiliations
- Fredric Rieders Family Foundation (US)
- Ghent University (BE)
- Corresponding author
- Stove, Christophe P.
- Vandeputte, Marthe M.
- ORCID
- Venue
- Archives of Toxicology
- Published
- 2024-06-14
- Volume
- 98
- Issue
- 9
- Pages
- 2999-3018
- ISSN
- 0340-5761 (ISSN-L)
- 1432-0738
- PMC
- PMC11324687
- OpenAlex
- W4399665315
- Cited by
- 58
- References
- 53
- Citations by year
- 2026: 22 · 2025: 31 · 2024: 5
- FWCI
- 13.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Archives of Toxicology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, cc-by)
- Funders
- Office of Justice Programs (15PNIJ-22-GG-04434-MUMU)
- Fonds Wetenschappelijk Onderzoek (11I5623N, 1S81522N, G069419N)
- Bijzonder Onderzoeksfonds UGent (BOF23/PDO/073, 01J15517)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Alkaloids: synthesis and pharmacology
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- structure-activity relationship, mu-opioid receptor, etonitazene, isotonitazene, opioid potency, forensic toxicology
- MeSH terms
- Analgesics, Opioid, Animals, Benzimidazoles, Humans, Nitro Compounds, Structure-Activity Relationship, Receptors, Opioid, mu, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.